Comparison of Fluconazole and Amphotericin B for Treatment of Experimental Candida Endocarditis Caused by Non-C. Albicans Strains

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1993 Sep 1

PMID 8239628

Citations 8

Authors

M D Witt

T Imhoff

C Li

A S Bayer

Affiliations

Soon will be listed here.

Abstract

Amphotericin B and fluconazole were compared for the treatment of experimental Candida endocarditis caused by Candida tropicalis and C. parapsilosis. Rabbits received no therapy, amphotericin B (1 mg/kg of body weight per day intravenously), or fluconazole (100 mg/kg/day intraperitoneally) for either 11 or 21 days. Against both species, amphotericin B and fluconazole were equally effective overall; however, amphotericin B was more rapidly fungicidal than fluconazole in vivo against C. tropicalis.

Citing Articles

Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations.

Pai M, Samples M, Mercier R, Spilde M Antimicrob Agents Chemother. 2008; 52(7):2367-76.

PMID: 18426896 PMC: 2443905. DOI: 10.1128/AAC.01557-07.

Invasive oesophageal candidiasis: current and developing treatment options.

Vazquez J Drugs. 2003; 63(10):971-89.

PMID: 12699400 DOI: 10.2165/00003495-200363100-00004.

Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.

Marchetti O, Entenza J, Sanglard D, Bille J, Glauser M, Moreillon P Antimicrob Agents Chemother. 2000; 44(11):2932-8.

PMID: 11036003 PMC: 101583. DOI: 10.1128/AAC.44.11.2932-2938.2000.

Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.

Aviles P, Falcoz C, San Roman R, Gargallo-Viola D Antimicrob Agents Chemother. 2000; 44(9):2333-40.

PMID: 10952576 PMC: 90066. DOI: 10.1128/AAC.44.9.2333-2340.2000.

Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.

Louie A, Liu Q, Drusano G, Liu W, Mayers M, Anaissie E Antimicrob Agents Chemother. 1998; 42(6):1512-4.

PMID: 9624506 PMC: 105634. DOI: 10.1128/AAC.42.6.1512.

References

Edwards Jr J, Filler S . Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis. 1992; 14 Suppl 1:S106-13. DOI: 10.1093/clinids/14.supplement_1.s106. View

Witt M, Bayer A . Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis. Antimicrob Agents Chemother. 1991; 35(12):2481-5. PMC: 245416. DOI: 10.1128/AAC.35.12.2481. View

Durack D, Beeson P, Petersdorf R . Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol. 1973; 54(2):142-51. PMC: 2072580. View

Seelig M, Speth C, Kozinn P, TASCHDJIAN C, Toni E, Goldberg P . Patterns of Candida endocarditis following cardiac surgery: Importance of early diagnosis and therapy (an analysis of 91 cases). Prog Cardiovasc Dis. 1974; 17(2):125-60. DOI: 10.1016/0033-0620(74)90027-9. View

Turnier E, KAY J, Bernstein S, Mendez A, Zubiate P . Surgical treatment of Candida endocarditis. Chest. 1975; 67(3):262-8. DOI: 10.1378/chest.67.3.262. View

Rubinstein E, Noriega E, Simberkoff M, Holzman R, Rahal Jr J . Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore). 1975; 54(4):331-4. View

Wiley E, Hutchins G . Superior vena cava syndrome secondary to Candida thrombophlebitis complicating parenteral alimentation. J Pediatr. 1977; 91(6):977-9. DOI: 10.1016/s0022-3476(77)80908-6. View

Wingard J, Merz W, Saral R . Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med. 1979; 91(4):539-43. DOI: 10.7326/0003-4819-91-4-539. View

Seelig M, Kozinin P, Goldberg P, Berger A . Fungal endocarditis: patients at risk and their treatment. Postgrad Med J. 1979; 55(647):632-41. PMC: 2425646. DOI: 10.1136/pgmj.55.647.632. View

10.

Rotrosen D, Calderone R, Edwards Jr J . Adherence of Candida species to host tissues and plastic surfaces. Rev Infect Dis. 1986; 8(1):73-85. DOI: 10.1093/clinids/8.1.73. View

11.

Doscher W, Krishnasastry K, DECKOFF S . Fungal graft infections: case report and review of the literature. J Vasc Surg. 1987; 6(4):398-402. DOI: 10.1067/mva.1987.avs0060398. View

12.

Saag M, Dismukes W . Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988; 32(1):1-8. PMC: 172087. DOI: 10.1128/AAC.32.1.1. View

13.

Powderly W, Kobayashi G, Herzig G, Medoff G . Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988; 84(5):826-32. DOI: 10.1016/0002-9343(88)90059-9. View

14.

TUCKER R, Williams P, Arathoon E, LeVine B, Hartstein A, Hanson L . Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother. 1988; 32(3):369-73. PMC: 172178. DOI: 10.1128/AAC.32.3.369. View

15.

Blinkhorn R, Adelstein D, Spagnuolo P . Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol. 1989; 27(2):236-40. PMC: 267283. DOI: 10.1128/jcm.27.2.236-240.1989. View

16.

Crislip M, Edwards Jr J . Candidiasis. Infect Dis Clin North Am. 1989; 3(1):103-33. View

17.

Komshian S, Uwaydah A, Sobel J, Crane L . Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989; 11(3):379-90. DOI: 10.1093/clinids/11.3.379. View

18.

Gallis H, Drew R, Pickard W . Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990; 12(2):308-29. DOI: 10.1093/clinids/12.2.308. View